Results 91 to 100 of about 15,072 (244)

Willingness to pay for a reduction in the mortality risk after a myocardial infarction: an aplication of the contingent valuation method to the case of eplerenone [PDF]

Background: In order to allocate health care resources more efficiently it is necessary to relate health improvements provided by new medicines with their cost.
Jaime Fernández de Bobadilla, Jose Luis Pinto-Prades, Veronica Farreras   +2 more
core  

Emerging methods for subtype differentiation in primary aldosteronism

Journal of Internal Medicine, Volume 299, Issue 2, Page 178-195, February 2026.
Abstract Primary aldosteronism (PA) is a common cause of hypertension. Compared to patients with essential hypertension, untreated PA is associated with a two‐ to fourfold greater risk of cardiovascular disease, renal failure, and death. PA is caused by increased secretion of aldosterone from one adrenal gland in 30% of the patients and both adrenal ...
Oskar Ragnarsson, C. Christofer Juhlin, Tobias Åkerström, Per Dahlqvist, Henrik Falhammar, Per Hellman   +5 more
wiley   +1 more source

Treatment of Heart Failure with Preserved Ejection Fraction [PDF]

, 2011
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90240/1/phco.31.3.312 ...
Barnes, Megan M., Bleske, Barry E., Dorsch, Michael P., Hummel, Scott L., Koelling, Todd M.   +4 more
core   +1 more source

Eplerenone-Mediated Aldosterone Blockade Prevents Renal Fibrosis by Reducing Renal Inflammation, Interstitial Cell Proliferation and Oxidative Stress

Kidney & Blood Pressure Research, 2013
Background/Aims: Prolonged elevation of serum aldosterone leads to renal fibrosis. Inflammation also plays a role in the pathogenesis of renal disease.
Hui Chen, Feng Sun, Xiaoshi Zhong, Yuebin Shao, Ashio Yoshimura, Yan Liu   +5 more
doaj   +1 more source

Endothelial Dysfunction in Human Essential Hypertension [PDF]

, 2016
Although the endothelium has a number of important functions, the term endothelial dysfunction is commonly used to describe impairment in its vasodilatory capacity.
Akiyama, Alexander, Anderson, Antony, Benjamin, Blanco-Rivero, Brehm, Brundtland, Cardillo, Cardillo, Ceconi, Celermajer, Charakida, Charakida, Cockcroft, Corretti, Corretti, Creager, Dawes, Deanfield, Dell’Omo, Deng, Dorresteijn, Dzau, d’Uscio, Erdos, Ergul, Fargin, Farquharson, Fischer, Flammer, Forstermann, Frielingsdorf, Fujimura, Furchgott, Gao, Garnier, Gaziano, Ghiadoni, Ghiadoni, Ghiadoni, Gokce, Gryglewski, Halcox, Hamburg, Haynes, Higashi, Hirooka, Hornig, Imai, Joannides, Juonala, Karthikeyan, Kerth, Kielstein, Kiowski, Klingbeil, Kobayashi, Koh, Kohno, Korkmaz, Krum, Kuvin, Lawes, Linder, Ludmer, Luscher, Luscher, Lyons, Mancia, Mancini, Millgard, Millgard, Modena, Morimoto, Muiesan, Muiesan, Murad, Nakamura, Nitenberg, Panza, Panza, Panza, Park, Pasini, Peller, Perticone, Perticone, Reriani, Rizzoni, Rizzoni, Romero, Rossi, Rossi, Roustit, Roustit, Rubanyi, Rubanyi, Russell, Savoia, Schiffrin, Schiffrin, Schiffrin, Schiffrin, Schiffrin, Schiffrin, Siegrist, Siragy, Suwaidi, Suzuki, Taddei, Taddei, Taddei, Taddei, Taddei, Takiguchi, Tiryaki, Troost, Turner, Tzemos, Tzemos, Ullian, van Hecke, Vanhoutte, Vinereanu, Virdis, Virdis, Vitale, Wagner, Weil, Wilkinson, Wood, Yamanari, Yanagisawa, Yavuz, Yilmaz, Zhang, Zhou   +137 more
core   +3 more sources

Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone [PDF]

, 2011
Background Inhibition of the renin-angiotensin-aldosterone system (RAAS) slows down the progression of chronic renal diseases (CKD) including IgA nephropathy (IgAN). Herein, we studied the pathogenetic roles of aldosterone (Aldo) in IgAN.
Joseph CK Leung, Loretta YY Chan, Sydney CW Tang, Man-Fai Lam, Chui-Wa Chow, Ai-Ing Lim, Kar-Neng Lai   +6 more
core   +2 more sources

Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice

International Journal of Hypertension, 2019
Eplerenone, a mineralocorticoid receptor antagonist (MRA), is available in Japan, but details of its use in clinical settings have not been thoroughly investigated.
Shoko Takahashi, Yoichi Ii, Yuji Yamamoto, Aya Ikeda, Yoko Fujimoto   +4 more
doaj   +1 more source

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease [PDF]

, 2015
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218 ...
Albert, Allen, Bayes-Genis, Berry, Bettencourt, Butler, Bärfacker, Dunlay, Edwards, Eschalier, Ezekowitz, Frantz, Fruhwald, Gheorghiade, Gheorghiade, Gheorghiade, Hamm, Hartmann, Iraqi, Juurlink, Kolkhof, Kolkhof, Maggioni, Maggioni, Maggioni, Masson, McMurray, Orena, Pascual-Figal, Pitt, Pitt, Skali, Tsutamoto, Udelson, Verdiani, Wright, Yamaji, Yamaji, Yancy, Zannad   +39 more
core   +2 more sources

Epidermal mineralocorticoid receptor plays beneficial and adverse effects in skin and mediates glucocorticoid responses [PDF]

, 2016
10 páginas, 6 figuras. Contiene material suplementarioGlucocorticoids (GCs) regulate skin homeostasis and combat cutaneous inflammatory diseases; however, adverse effects of chronic GC treatments limit their therapeutic use.
Boix, Julia, Carceller, Elena, Pérez, Paloma, Sevilla, Lisa M., Sáez, Zara   +4 more
core   +1 more source

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

Orphanet Journal of Rare Diseases, 2017
Background Cardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). We recently showed in a 12-month double-blind randomized controlled trial that adding eplerenone to background medical therapy was ...
Subha V. Raman, Kan N. Hor, Wojciech Mazur, Xin He, John T. Kissel, Suzanne Smart, Beth McCarthy, Sharon L. Roble, Linda H. Cripe   +8 more
doaj   +1 more source